{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:16:29Z","timestamp":1778411789820,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41443-022-00656-3","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T10:02:44Z","timestamp":1672048964000},"page":"181-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Understanding the dopaminergic pathway relative to men\u2019s sexual dysfunction in patients with Parkinson\u2019s disease: a narrative review with implications for future research"],"prefix":"10.1038","volume":"36","author":[{"given":"Nicholas A.","family":"Deebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Thai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjith","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-0497","authenticated-orcid":false,"given":"Ryan P.","family":"Terlecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"656_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S, Peter GB, Chaudhuri KR, Piccini P. Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord. 2010;25:1646\u201351.","journal-title":"Mov Disord"},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jsxm.2018.12.017","volume":"16","author":"S Zhao","year":"2019","unstructured":"Zhao S, Wang J, Xie Q, Luo L, Zhu Z, Liu Y, et al. Parkinson\u2019s Disease is associated with risk of sexual dysfunction in men but not in women: a systematic review and meta-analysis. J Sex Med. 2019;16:434\u201346.","journal-title":"J Sex Med"},{"key":"656_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/2054-7072-1-8","volume":"1","author":"MS Okun","year":"2014","unstructured":"Okun MS, Wu SS, Jennings D, Marek K, Rodriguez RL, Fernandez HH. Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. J Clin Mov Disord. 2014;1:8.","journal-title":"J Clin Mov Disord"},{"key":"656_CR4","first-page":"60","volume":"14","author":"C Savci","year":"2009","unstructured":"Savci C, Sendir M. Evaluation of health related quality of life in patients with Parkinsons disease. Neurosciences. 2009;14:60\u201366.","journal-title":"Neurosciences"},{"key":"656_CR5","doi-asserted-by":"crossref","unstructured":"Kinateder T, Marinho D, Gruber D, Hatzler L, Ebersbach G, Gandor F. Sexual Dysfunctions in Parkinson\u2019s Disease and Their Influence on Partnership-Data of the PRISM Study. Brain Sci 2022; 12.","DOI":"10.3390\/brainsci12020159"},{"key":"656_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis. 2018;4:21.","journal-title":"NPJ Parkinsons Dis"},{"key":"656_CR7","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.arr.2022.101665","volume":"79","author":"YF Ng","year":"2022","unstructured":"Ng YF, Chen CY, Chia GT, Tan BBJ, Chan LL, Tan EK. The association between Parkinson\u2019s disease and Sexual dysfunction: Clinical correlation and therapeutic implications. Ageing Res Rev. 2022;79:101665.","journal-title":"Ageing Res Rev"},{"key":"656_CR8","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.jsxm.2020.06.010","volume":"17","author":"L Raciti","year":"2020","unstructured":"Raciti L, De Cola MC, Ortelli P, Corallo F, Lo Buono V, Morini E, et al. Sexual dysfunction in Parkinson Disease: a multicenter italian cross-sectional study on a still overlooked problem. J Sex Med. 2020;17:1914\u201325.","journal-title":"J Sex Med"},{"key":"656_CR9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","volume":"22","author":"N Ben-Jonathan","year":"2001","unstructured":"Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724\u201363.","journal-title":"Endocr Rev"},{"key":"656_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","volume":"200","author":"JP Mulhall","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423\u201332.","journal-title":"J Urol"},{"key":"656_CR11","first-page":"294","volume":"2","author":"M Bourque","year":"2021","unstructured":"Bourque M, Soulet D, Di Paolo T. Androgens and Parkinson\u2019s Disease: a review of human studies and animal models. Androg Clin Res Ther. 2021;2:294\u2013303.","journal-title":"Androg Clin Res Ther"},{"key":"656_CR12","first-page":"165","volume":"75","author":"MS Okun","year":"2004","unstructured":"Okun MS, Crucian GP, Fischer L, Walter BL, Testa CM, Vitek JL, et al. Testosterone deficiency in a Parkinson\u2019s disease clinic: results of a survey. J Neurol Neurosurg Psychiatry. 2004;75:165\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"656_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archneur.59.5.807","volume":"59","author":"MS Okun","year":"2002","unstructured":"Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59:807\u201311.","journal-title":"Arch Neurol"},{"key":"656_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1210\/jcem-34-4-756","volume":"34","author":"SB Sinhamahapatra","year":"1972","unstructured":"Sinhamahapatra SB, Kirschner MA. Effect of L-dopa on testosterone and luteinizing hormone production. J Clin Endocrinol Metab. 1972;34:756\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"656_CR15","first-page":"129","volume":"51","author":"A Pekkarinen","year":"1972","unstructured":"Pekkarinen A, Rinne UK, Salokangas R, Siirtola T, Sonninen V. Plasma testosterone content of male patients with Parkinson\u2019s disease during L-dopa treatment with or without dopadecarboxylase inhibitor. Acta Neurol Scand Suppl. 1972;51:129\u201330.","journal-title":"Acta Neurol Scand Suppl"},{"key":"656_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF00319704","volume":"238","author":"G Bellomo","year":"1991","unstructured":"Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson\u2019s disease. J Neurol. 1991;238:19\u201322.","journal-title":"J Neurol"},{"key":"656_CR17","first-page":"3","volume":"50","author":"K Otake","year":"1994","unstructured":"Otake K, Oiso Y, Mitsuma T, Hirooka Y, Adachi K. Hypothalamic dysfunction in Parkinson\u2019s disease patients. Acta Med Hung. 1994;50:3\u201313.","journal-title":"Acta Med Hung"},{"key":"656_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/CMED.S14902","volume":"7","author":"JS Daniel","year":"2014","unstructured":"Daniel JS, Govindan JP, Kamath C, D\u2019Souza C, Adlan MA, Premawardhana LD. Newer dopaminergic agents cause minimal endocrine effects in idiopathic Parkinson\u2019s disease. Clin Med Insights Endocrinol Diabetes. 2014;7:13\u201317.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"656_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ane.12334","volume":"131","author":"M Nitkowska","year":"2015","unstructured":"Nitkowska M, Tomasiuk R, Czyzyk M, Friedman A. Prolactin and sex hormones levels in males with Parkinson\u2019s disease. Acta Neurol Scand. 2015;131:411\u20136.","journal-title":"Acta Neurol Scand"},{"key":"656_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000519552","volume":"29","author":"H Duc Nguyen","year":"2022","unstructured":"Duc Nguyen H, Hoang NMH, Ko M, Seo D, Kim S, Jo WH, et al. Association between serum prolactin levels and neurodegenerative diseases: systematic review and meta-analysis. Neuroimmunomodulation. 2022;29:85\u201396.","journal-title":"Neuroimmunomodulation"},{"key":"656_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mds.870080223","volume":"8","author":"VS Kostic","year":"1993","unstructured":"Kostic VS, Marinkovic Z, Filipovic S, Momcilovic D. Function of dopamine receptors in young-onset Parkinson\u2019s disease: prolactin response. Mov Disord. 1993;8:227\u20139.","journal-title":"Mov Disord"},{"key":"656_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0404.1991.tb04666.x","volume":"83","author":"G Cusimano","year":"1991","unstructured":"Cusimano G, Capriani C, Bonifati V, Meco G. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients. Acta Neurol Scand. 1991;83:145\u201350.","journal-title":"Acta Neurol Scand"},{"key":"656_CR23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/jnnp.43.11.1012","volume":"43","author":"NF Lawton","year":"1980","unstructured":"Lawton NF, MacDermot J. Abnormal regulation of prolactin release in idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1980;43:1012\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"656_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/WNL.31.10.1356","volume":"31","author":"T Eisler","year":"1981","unstructured":"Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB. Prolactin secretion in Parkinson disease. Neurology. 1981;31:1356\u20139.","journal-title":"Neurology"},{"key":"656_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s13311-020-00897-4","volume":"17","author":"RF Pfeiffer","year":"2020","unstructured":"Pfeiffer RF. Autonomic dysfunction in Parkinson\u2019s Disease. Neurotherapeutics. 2020;17:1464\u201379.","journal-title":"Neurotherapeutics"},{"key":"656_CR26","doi-asserted-by":"crossref","unstructured":"Elshamy AM, Mohamed ES, Al-Malt AM, Ragab OA. Sexual dysfunction among egyptian idiopathic Parkinson\u2019s Disease patients. J Geriatr Psychiatry Neurol. 2022;35:816\u201322.","DOI":"10.1177\/08919887211063810"},{"key":"656_CR27","first-page":"518","volume":"19","author":"X Hu","year":"2013","unstructured":"Hu X, Liu WG, Yan FL. [Male sexual dysfunction and Parkinson\u2019s disease: a preliminary investigation]. Zhonghua Nan Ke Xue. 2013;19:518\u201321.","journal-title":"Zhonghua Nan Ke Xue"},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/1756285611411504","volume":"4","author":"G Bronner","year":"2011","unstructured":"Bronner G, Vodusek DB. Management of sexual dysfunction in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2011;4:375\u201383.","journal-title":"Ther Adv Neurol Disord"},{"key":"656_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","volume":"92","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson\u2019s disease. Auton Neurosci. 2001;92:76\u201385.","journal-title":"Auton Neurosci"},{"key":"656_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/mds.22519","volume":"25","author":"R Sakakibara","year":"2010","unstructured":"Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson\u2019s disease. Mov Disord. 2010;25:2\u201312.","journal-title":"Mov Disord"},{"key":"656_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1017\/S0317167100010209","volume":"37","author":"M Parent","year":"2010","unstructured":"Parent M, Parent A. Substantia nigra and Parkinson\u2019s disease: a brief history of their long and intimate relationship. Can J Neurol Sci. 2010;37:313\u20139.","journal-title":"Can J Neurol Sci"},{"key":"656_CR32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of parkinson disease: a review. JAMA. 2020;323:548\u201360.","journal-title":"JAMA"},{"key":"656_CR33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1192\/bjp.153.6.833","volume":"153","author":"NS Harvey","year":"1988","unstructured":"Harvey NS. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry. 1988;153:833\u20136.","journal-title":"Br J Psychiatry"},{"key":"656_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-2007-1017459","volume":"16","author":"HP Vogel","year":"1983","unstructured":"Vogel HP, Schiffter R. Hypersexuality\u2013a complication of dopaminergic therapy in Parkinson\u2019s disease. Pharmacopsychiatria. 1983;16:107\u201310.","journal-title":"Pharmacopsychiatria"},{"key":"656_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","volume":"12","author":"RJ Uitti","year":"1989","unstructured":"Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. 1989;12:375\u201383.","journal-title":"Clin Neuropharmacol"},{"key":"656_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/01.mjt.0000151861.59698.26","volume":"12","author":"LS Ivanco","year":"2005","unstructured":"Ivanco LS, Bohnen NI. Effects of donepezil on compulsive hypersexual behavior in Parkinson disease: a single case study. Am J Ther. 2005;12:467\u20138.","journal-title":"Am J Ther"},{"key":"656_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1212\/WNL.52.1.210-a","volume":"52","author":"FJ Jimenez-Jimenez","year":"1999","unstructured":"Jimenez-Jimenez FJ, Tallon-Barranco A, Cabrera-Valdivia F, Gasalla T, Orti-Pareja M, Zurdo M. Fluctuating penile erection related with levodopa therapy. Neurology. 1999;52:210.","journal-title":"Neurology"},{"key":"656_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1468-1331.2004.00820.x","volume":"11","author":"M Pohanka","year":"2004","unstructured":"Pohanka M, Kanovsky P, Bares M, Pulkrabek J, Rektor I. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson\u2019s disease: the results of an open, prospective, 6-month follow-up. Eur J Neurol. 2004;11:483\u20138.","journal-title":"Eur J Neurol"},{"key":"656_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4081\/aiua.2022.1.107","volume":"94","author":"M Moussa","year":"2022","unstructured":"Moussa M, Abou Chakra M, Papatsoris AG, Dellis A, Dabboucy B, Peyromaure M, et al. Perspectives on the urological care in Parkinson\u2019s disease patients. Arch Ital Urol Androl. 2022;94:107\u201317.","journal-title":"Arch Ital Urol Androl"},{"key":"656_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","volume":"68","author":"AA Moustafa","year":"2016","unstructured":"Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinson\u2019s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727\u201340.","journal-title":"Neurosci Biobehav Rev"},{"key":"656_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical E. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345.","journal-title":"Lancet Neurol"},{"key":"656_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jocn.2005.02.014","volume":"13","author":"E Mitchell","year":"2006","unstructured":"Mitchell E, Thomas D, Burnet R. Testosterone improves motor function in Parkinson\u2019s disease. J Clin Neurosci. 2006;13:133\u20136.","journal-title":"J Clin Neurosci"},{"key":"656_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archneur.63.5.729","volume":"63","author":"MS Okun","year":"2006","unstructured":"Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Arch Neurol. 2006;63:729\u201335.","journal-title":"Arch Neurol"},{"key":"656_CR44","first-page":"4495","volume":"16","author":"MA Elshaikh","year":"2009","unstructured":"Elshaikh MA, Underwood W, Soto DE. Androgen deprivation therapy for patients with prostate carcinoma and Parkinson\u2019s disease: case report and review of literature. Can J Urol. 2009;16:4495\u20137.","journal-title":"Can J Urol"},{"key":"656_CR45","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00345-017-2010-z","volume":"35","author":"JWS Young","year":"2017","unstructured":"Young JWS, Sutradhar R, Rangrej J, Marras C, Fleshner N, Alibhai SMH. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer. World J Urol. 2017;35:1417\u201323.","journal-title":"World J Urol"},{"key":"656_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/andr.12187","volume":"4","author":"SD Chung","year":"2016","unstructured":"Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC. Androgen deprivation therapy did not increase the risk of Alzheimer\u2019s and Parkinson\u2019s disease in patients with prostate cancer. Andrology. 2016;4:481\u20135.","journal-title":"Andrology"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00656-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00656-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T09:04:23Z","timestamp":1713776663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-022-00656-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1038\/s41443-022-00656-3","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}